Five things for pharma marketers to know: Friday, September 22, 2017

Share this content:


1. Express Scripts chief medical officer Steve Miller wrote in a blog post that there needs to be new models to pay for CAR-T therapies. He cited Novartis' recently approved Kymriah, an innovative new treatment for a certain kind of acute lymphoblastic leukemia. (Express Scripts)

2. The FDA warned doctors that it received adverse event reports detailing 19 deaths in patients taking Intercept Pharmaceuticals' Ocaliva, a drug to treat a rare liver disease. Intercept is studying Ocaliva as a treatment for NASH, another disease of the liver.  (Bloomberg)

3. In other FDA news, the agency offered up new draft guidance for biosimilars. The draft provides guidance to drugmakers that hope to demonstrate that their biosimilars are “highly similar” to a reference product. (RAPS)

4. CVS Health said it would enforce new limits on opioid prescriptions. The pharmacy benefit manager will limit patients who have never been prescribed an opioid to a seven-day supply of medication. (STAT)

5. The National Association of Medicaid Directors said in a statement that Sens. Lindsey Graham's (R-SC) and Bill Cassidy's (R-LA) proposed healthcare bill would “pose serious challenges for states.” The bill would end Obamacare's Medicaid expansion, replacing it with state block grants. (The Hill)

Share this content:
Scroll down to see the next article